Capricor Therapeutics (CAPR) News Today $7.33 -2.97 (-28.80%) Closing price 03:59 PM EasternExtended Trading$7.50 +0.16 (+2.20%) As of 07:32 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 Time Period Capricor Therapeutics to Present First Quarter 2025 Financial Results and Recent Corporate Update on May 13May 6 at 9:15 AM | globenewswire.comCapricor Therapeutics Inc (NASDAQ:CAPR) Stock Position Lessened by JPMorgan Chase & Co.JPMorgan Chase & Co. decreased its stake in Capricor Therapeutics Inc (NASDAQ:CAPR - Free Report) by 70.3% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 16,680 shares of the biotechnology company's stock after selling 39,519May 6 at 3:05 AM | marketbeat.comCapricor Therapeutics Stock Tumbles After FDA Confirms Intent To Hold Advisory Committee Meet For Deramiocel Approval: But Retail’s OptimisticMay 5 at 2:52 PM | msn.comUS FDA to convene expert panel for Capricor Therapeutics' DMD cell therapyMay 5 at 11:08 AM | reuters.comCapricor Therapeutics Announces Completion of Mid-Cycle Review Meeting with FDA on Deramiocel for the Treatment of Duchenne Muscular Dystrophy CardiomyopathyMay 5 at 8:00 AM | globenewswire.comCapricor Therapeutics (NASDAQ:CAPR) Shares Down 4.7% - Time to Sell?Capricor Therapeutics (NASDAQ:CAPR) Shares Down 4.7% - Time to Sell?May 5 at 4:56 AM | marketbeat.com59,303 Shares in Capricor Therapeutics Inc (NASDAQ:CAPR) Purchased by Marshall Wace LLPMarshall Wace LLP bought a new stake in shares of Capricor Therapeutics Inc (NASDAQ:CAPR - Free Report) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 59,303 shares of the biotechnology company's stockMay 3 at 3:47 AM | marketbeat.comCapricor Therapeutics Inc (NASDAQ:CAPR) Receives Average Recommendation of "Buy" from BrokeragesCapricor Therapeutics Inc (NASDAQ:CAPR - Get Free Report) has been given a consensus rating of "Buy" by the six research firms that are covering the firm, Marketbeat.com reports. Six research analysts have rated the stock with a buy rating. The average 1-year price objective among analysts that haMay 2, 2025 | marketbeat.comLegal & General Group Plc Grows Stock Position in Capricor Therapeutics Inc (NASDAQ:CAPR)Legal & General Group Plc lifted its position in Capricor Therapeutics Inc (NASDAQ:CAPR - Free Report) by 1,029.7% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 30,783 shares of the biotechnology company's sMay 2, 2025 | marketbeat.comPiper Sandler Sticks to Its Buy Rating for Capricor Therapeutics (CAPR)April 26, 2025 | markets.businessinsider.comCapricor Therapeutics (NASDAQ:CAPR) Trading 4.8% Higher - Here's WhyCapricor Therapeutics (NASDAQ:CAPR) Stock Price Up 4.8% - Here's WhyApril 23, 2025 | marketbeat.comCapricor Therapeutics Inc (NASDAQ:CAPR) Stock Holdings Increased by Geode Capital Management LLCGeode Capital Management LLC raised its holdings in shares of Capricor Therapeutics Inc (NASDAQ:CAPR - Free Report) by 37.8% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 879,468 shares of the biotechnology company's stock afterApril 23, 2025 | marketbeat.comCapricor Therapeutics Inc (CAPR) Q4 2024 Earnings Call Highlights: Navigating Financial ...April 21, 2025 | gurufocus.comEAM Investors LLC Has $528,000 Position in Capricor Therapeutics Inc (NASDAQ:CAPR)EAM Investors LLC decreased its holdings in shares of Capricor Therapeutics Inc (NASDAQ:CAPR - Free Report) by 45.3% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 38,276 shares of the biotechnolApril 20, 2025 | marketbeat.comCapricor Therapeutics Inc (NASDAQ:CAPR) Shares Bought by Altium Capital Management LLCAltium Capital Management LLC lifted its position in shares of Capricor Therapeutics Inc (NASDAQ:CAPR - Free Report) by 150.5% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 714,000 shares of the biotechnology company's stockApril 19, 2025 | marketbeat.com144,250 Shares in Capricor Therapeutics Inc (NASDAQ:CAPR) Acquired by Kennedy Capital Management LLCKennedy Capital Management LLC purchased a new stake in Capricor Therapeutics Inc (NASDAQ:CAPR - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund purchased 144,250 shares of the biotechnology company'sApril 17, 2025 | marketbeat.comWellington Management Group LLP Invests $565,000 in Capricor Therapeutics Inc (NASDAQ:CAPR)Wellington Management Group LLP purchased a new stake in Capricor Therapeutics Inc (NASDAQ:CAPR - Free Report) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 40,959 shares of the biotecApril 16, 2025 | marketbeat.comVanguard Group Inc. Purchases 700,243 Shares of Capricor Therapeutics Inc (NASDAQ:CAPR)Vanguard Group Inc. raised its position in Capricor Therapeutics Inc (NASDAQ:CAPR - Free Report) by 44.4% during the 4th quarter, according to its most recent filing with the SEC. The institutional investor owned 2,276,784 shares of the biotechnology company's stock after acquiring an additional 7April 15, 2025 | marketbeat.comCapricor Therapeutics Inc (NASDAQ:CAPR) Given Consensus Rating of "Buy" by BrokeragesShares of Capricor Therapeutics Inc (NASDAQ:CAPR - Get Free Report) have earned a consensus rating of "Buy" from the six brokerages that are covering the stock, MarketBeat reports. Six research analysts have rated the stock with a buy recommendation. The average 12 month target price among brokeraApril 7, 2025 | marketbeat.comCantor Fitzgerald Issues Positive Outlook for CAPR EarningsCapricor Therapeutics Inc (NASDAQ:CAPR - Free Report) - Research analysts at Cantor Fitzgerald increased their FY2025 EPS estimates for Capricor Therapeutics in a report issued on Tuesday, April 1st. Cantor Fitzgerald analyst K. Kluska now anticipates that the biotechnology company will earn ($1.April 5, 2025 | marketbeat.comCapricor Therapeutics to Present at the 2025 Piper Sandler Virtual Cardio DayApril 1, 2025 | markets.businessinsider.comSwiss National Bank Acquires New Stake in Capricor Therapeutics Inc (NASDAQ:CAPR)Swiss National Bank acquired a new stake in Capricor Therapeutics Inc (NASDAQ:CAPR - Free Report) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 67,400 shares of the biotechnology company's stock, valued at approximateMarch 30, 2025 | marketbeat.comCharles Schwab Investment Management Inc. Has $1.54 Million Holdings in Capricor Therapeutics Inc (NASDAQ:CAPR)Charles Schwab Investment Management Inc. raised its stake in Capricor Therapeutics Inc (NASDAQ:CAPR - Free Report) by 51.5% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 111,336 shares of the biotechnology company'sMarch 30, 2025 | marketbeat.comCapricor Therapeutics (NASDAQ:CAPR) Stock Price Down 4.7% - Here's What HappenedCapricor Therapeutics (NASDAQ:CAPR) Trading Down 4.7% - Should You Sell?March 28, 2025 | marketbeat.comCheck Out What Whales Are Doing With CAPRMarch 28, 2025 | benzinga.comBank of New York Mellon Corp Purchases 20,638 Shares of Capricor Therapeutics Inc (NASDAQ:CAPR)Bank of New York Mellon Corp boosted its stake in shares of Capricor Therapeutics Inc (NASDAQ:CAPR - Free Report) by 32.6% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 84,027 shares of the biotechnology cMarch 25, 2025 | marketbeat.comWhat is HC Wainwright's Forecast for CAPR Q1 Earnings?Capricor Therapeutics Inc (NASDAQ:CAPR - Free Report) - HC Wainwright issued their Q1 2025 earnings estimates for Capricor Therapeutics in a report issued on Thursday, March 20th. HC Wainwright analyst J. Pantginis forecasts that the biotechnology company will earn ($0.35) per share for the quartMarch 24, 2025 | marketbeat.comResearch Analysts Offer Predictions for CAPR Q2 EarningsCapricor Therapeutics Inc (NASDAQ:CAPR - Free Report) - Equities research analysts at HC Wainwright issued their Q2 2025 earnings per share estimates for Capricor Therapeutics in a research report issued to clients and investors on Thursday, March 20th. HC Wainwright analyst J. Pantginis expectsMarch 22, 2025 | marketbeat.comCapricor Therapeutics Announces FDA Acceptance of Biologics License Application for Deramiocel in Duchenne Muscular Dystrophy CardiomyopathyMarch 21, 2025 | nasdaq.comCapricor Therapeutics Target of Unusually High Options Trading (NASDAQ:CAPR)Capricor Therapeutics Inc (NASDAQ:CAPR - Get Free Report) was the target of unusually large options trading activity on Thursday. Investors acquired 11,316 call options on the stock. This represents an increase of approximately 214% compared to the typical volume of 3,599 call options.March 21, 2025 | marketbeat.comIs Capricor Therapeutics (CAPR) a Worst High-Risk High-Reward Growth Stock to Buy?March 21, 2025 | msn.comCapricor Therapeutics Full Year 2024 Earnings: Beats ExpectationsMarch 21, 2025 | finance.yahoo.comCapricor Therapeutics (NASDAQ:CAPR) Shares Gap Up After Strong EarningsCapricor Therapeutics (NASDAQ:CAPR) Shares Gap Up After Better-Than-Expected EarningsMarch 21, 2025 | marketbeat.comCantor Fitzgerald Reiterates Overweight Rating for Capricor Therapeutics (NASDAQ:CAPR)Cantor Fitzgerald restated an "overweight" rating and issued a $30.00 target price on shares of Capricor Therapeutics in a research note on Thursday.March 21, 2025 | marketbeat.comCapricor Therapeutics (NASDAQ:CAPR) Announces Earnings Results, Beats Expectations By $0.15 EPSCapricor Therapeutics (NASDAQ:CAPR - Get Free Report) posted its quarterly earnings data on Wednesday. The biotechnology company reported ($0.16) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.31) by $0.15. Capricor Therapeutics had a negative return on equity of 112.95% and a negative net margin of 146.86%.March 20, 2025 | marketbeat.comQ4 2024 Capricor Therapeutics Inc Earnings CallMarch 20, 2025 | uk.finance.yahoo.comCapricor Therapeutics Stock Surges After Q4 Results Beat Estimates: Retail Gets More BullishMarch 20, 2025 | msn.com2CAPR : A Glimpse Into The Expert Outlook On Capricor Therapeutics Through 4 AnalystsMarch 20, 2025 | benzinga.comCapricor projects FDA priority review decision for deramiocel by August 2025March 20, 2025 | msn.comCapricor Therapeutics options imply 8.9% move in share price post-earningsMarch 20, 2025 | markets.businessinsider.comQ4 2024 Capricor Therapeutics Inc Earnings Call TranscriptMarch 20, 2025 | gurufocus.comCapricor Therapeutics Inc Reports Q4 2024 Earnings: EPS Loss of $0. ...March 19, 2025 | gurufocus.comCapricor Therapeutics beats Q4 estimates, shares rise on FDA acceptanceMarch 19, 2025 | ca.investing.comWhile institutions own 38% of Capricor Therapeutics, Inc. (NASDAQ:CAPR), retail investors are its largest shareholders with 49% ownershipMarch 19, 2025 | finance.yahoo.comCapricor Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate UpdateMarch 19, 2025 | globenewswire.comCapricor Therapeutics (NASDAQ:CAPR) Shares Down 6% - What's Next?Capricor Therapeutics (NASDAQ:CAPR) Trading Down 6% - What's Next?March 19, 2025 | marketbeat.comCapricor Announces 52% Slowing Of Disease Progression In DMD With Deramiocel TreatmentMarch 19, 2025 | nasdaq.comCapricor Announces 52% Slowing Of Disease Progression In DMD With Deramiocel TreatmentMarch 19, 2025 | nasdaq.comCapricor Therapeutics Q4 2024 Earnings PreviewMarch 18, 2025 | msn.comCapricor Therapeutics (NASDAQ:CAPR) Receives Buy Rating from HC WainwrightHC Wainwright reissued a "buy" rating and issued a $77.00 target price on shares of Capricor Therapeutics in a research report on Monday.March 18, 2025 | marketbeat.com Get Capricor Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CAPR and its competitors with MarketBeat's FREE daily newsletter. Email Address CAPR Media Mentions By Week CAPR Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CAPR News Sentiment▼0.980.69▲Average Medical News Sentiment CAPR News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CAPR Articles This Week▼94▲CAPR Articles Average Week Get Capricor Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CAPR and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies ARQT News Today BHC News Today SUPN News Today CNTA News Today IDYA News Today GLPG News Today JANX News Today AGIO News Today EWTX News Today HRMY News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CAPR) was last updated on 5/6/2025 by MarketBeat.com Staff From Our PartnersBlackrock’s Sending THIS Crypto Higher on PurposeWhile everyone's distracted by Bitcoin's moves, a stealth revolution is underway. One altcoin is quietly po...Crypto 101 Media | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredElon just did WHAT!?As you may recall, Biden and the Fed were working on a central bank digital currency, or CBDC. Had they got...Brownstone Research | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredThis Is The Moment You Betray Trump (Or Prove Them Wrong)They said you wouldn’t last—that Bidenflation, Wall Street selloffs, and DEI funds would break your loyalty to...Colonial Metals | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Capricor Therapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Capricor Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy CAPR Stock Free CAPR Stock Alerts